Investor Presentation Q1-Q3 2020

29 Investor presentation First nine months of 2020 Novo Nordisk® Pipeline supports significant growth opportunities across all four strategic focus areas PHASE 1 NN1535 Icosema (LAIsema) NN1965 - Insulin 965 NN1147 Insulin 147 NN9389QW Sema + GIP NN1845 Glucose sensitive insulin NN9775 PYY 1875 analogue NN9215 LA-GDF15 NN9838 - AM833 and Sema NN7769 Mim8 (Phase 1/2) NN7533 Eclipse NN9500 FGF-21 NASH NN6434 PCSK9i NN6177 - GG-co-agonist PHASE 2 NN1436 Icodec (LAI287) NN9838-Amylin AM833 EX2020 Macrilen, GHD5 NN9931 - Semaglutide NASH NN9931 - Gilead NASH NN6018 - Ziltivekimab PHASE 3 SUBMITTED Semaglutide obesity Somapacitan - QW AGHD¹ SELECT Semaglutide 2.4 mg in obesity CVOT Somapacitan - QW GHD2 Concizumab SUSTAIN FORTE - Semaglutide 2.0 mg SOUL - Oral semaglutide CVOT FLOW - Semaglutide 1.0 mg in chronic kidney disease FOCUS Semaglutide 1.0 mg in diabetic retinopathy APPROVED Tresiba Ⓡ XultophyⓇ LevemirⓇ RyzodegⓇ NovoMixⓇ FiaspⓇ NovoRapidⓇ VictozaⓇ OzempicⓇ RybelsusⓇ3 SaxendaⓇ NovoSevenⓇ NovoEight® STT-5058 STATEN, ApoC3 mAb Diabetes Obesity Haemophilia Growth Disorders NovoThirteenⓇ RefixiaⓇ/RebinynⓇ NorditropinⓇ SogroyaⓇ6 Other serious chronic disease 1 Study conducted in adult growth hormone disorder; 2 Study conducted in growth hormone disorders; 3 Approved in the US, the EU, and Japan; submitted in Canada; 4 Study conducted in NASH; 5 Novo Nordisk only holds the commercial rights in North America; Approved in the US LAIsema: Long-acting insulin combined with semaglutide; PYY: Peptide YY; QW: Once-weekly; GG: Glucagon GLP-1; mAb: monocolonal antibody; GDF15: Growth differentiation factor 15; Sema: Semaglutide; FGF-21: Fibroblast growth factor 21; LAI: Long-acting insulin; AGHD: Adult growth hormone disease; GHD: Growth hormone disorder; lira: Liraglutide; Note: the obesity co-agonist and tri-agonist projects have been terminated

View entire presentation